Role of the BACE1-AS Long Noncoding RNA in Ischemic Heart Failure
The objective of this project is 1) to explore the clinical relevance of BACE1-AS and BACE1 as therapeutic targets and 2) to evaluate their potentiality as biomarkers in ischemic heart failure (HF). The first aim will be studied by validating in left ventricle biopsies in patients with post-ischemic heart failure the transcriptome and DNA methylation status data obtained in cell lines where the expression of BACE1-AS has been modulated. The investigation of BACE1-AS and BACE1 as biomarkers will be obtained by using peripheral blood mononuclear cells (PBMCs) from patients with acute coronary syndrome (ACS) treated with percutaneous angioplasty (PCI) procedure and undergoing to left ventricular remodeling. Furthermore, PBMCs from patients with chronic ischemic HF recruited from the Istituti Clinici Scientifici Maugeri Pavia will be also used. From the data obtained from these patients and from non-decompensated subjects, the levels of BACE1-AS and BACE1 in the blood will be measured and correlated with each other and with β-amyloid levels (βA), as well as with clinically relevant parameters.
⁃ left ventricular reconstruction surgery (SVR)
⁃ ESVI \>35 ml/m2
⁃ EF\<40%
⁃ previous anterior transmural infarction
⁃ age 40-75 years
⁃ Age \>18 years
⁃ Patients with ACS (first episode), defined according to the ESC 2017 guidelines \[19\]
⁃ Informed consent to enrollment in the study
• All patients admitted to Rehabilitation Cardiology at the Cardiology Department of ICS Maugeri with a diagnosis of chronic heart failure on an ischemic or acute basis due to exacerbation of chronic heart failure due to previous ischemia and whose therapies have been optimized at the moment of enlistment.
• NYHA Class II-III at the time of enlistment;
• Age over 18 years;
• Informed consent signed at the time of enrollment in the study.